Screening for fetal aneuploidy and neural tube defects

Genetics in Medicine

Volumn 11, Issue 11, 2009, Pages 818-821

  Driscoll, Deborah A ^a,c   Gross, Susan J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c 5 Dulles Building ^*  (United States)

Author keywords

Aneuploidy; Multiple marker screening; Nuchal translucency

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ANEUPLOIDY; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC MARKER; HUMAN; MEDICAL SOCIETY; NEURAL TUBE DEFECT; NUCHAL TRANSLUCENCY MEASUREMENT; PRACTICE GUIDELINE; PRENATAL DIAGNOSIS; SECOND TRIMESTER PREGNANCY; SHORT SURVEY;

BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; FETAL DISEASES; GENETIC MARKERS; GENETIC TESTING; HUMANS; NEURAL TUBE DEFECTS; PREGNANCY; PRENATAL DIAGNOSIS; TRISOMY;

EID: 73849092216     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181bb267b     Document Type: Short Survey

References (30)

1. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin Number 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217-227.
2. Wald NJ, Cuckle HS, Brock JH, Peto R, Polani PE, Woodford FP. Maternal serum alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of the U.K. Collaborative Study on alpha-etoprotein in relation to neural tube defects. Lancet 1977;1:1323-1332.
3. Milunsky A. Maternal serum screening for neural tube and other defects. In: Milunsky A, editor. Genetic disorders and the fetus: diagnosis, prevention, and treatment. 4th ed. Baltimore, MD: Johns Hopkins University Press, 1998:635-701.
4. Bradley LA, Palomaki GE, McDowell GA; ONTD Working Group; ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines: prenatal screening for open neural tube defects. Genet Med 2005;7: 355-369.
5. Cheschier N. ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin Number 44: neural tube defects. Int J Gynaecol 2003;83: 123-133.
6. Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003;3: CD003252.
7. Jackson LG, Zachary JM, Fowler SE, et al. The US National Institute of Child Health and Human Development Chorionic-Villous Sampling and Amniocentesis Study Group. A randomized comparison of transcervical and transabdominal chorionic-villous sampling. N Engl J Med 1992;327:594-598.
8. ACOG Committee on Practice Bulletins. ACOG Practice bulletin Number 88: invasive prenatal testing for aneuploidy. Obstet Gynecol 2007;110:1459-1466.
9. Eddelman KA, Malone FD, Sullivan L, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006;108:1067-1072.
10. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-624.
11. Malone F, Canick JA, Ball RH, et al. First-and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-2011.
12. Wapner R, Thom E, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-1413.
13. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM; SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum Urine and Ultrasound Screening Study (SURUSS) [erratum appears in J Med Screen 2006;13:51-52]. Health Technol Assess 2003;7:1-77.
14. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003;110:281-286. (Pubitemid 36298912)
15. Evans MI, Krantz DA, Hallahan TW, Galen RS. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. Am J Obstet Gynecol 2007;196:198-205.
16. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004;191:45-67.
17. Snijders RJ, Noble P, Sebire N, Souka A, et al. Fetal Medicine Foundation First Trimester Screening Group. UK multicenter project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998;351:343-346.
18. Comstock CH, Malone FD, Ball RH, et al. FASTER Research Consortium. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester screening? Am J Obstet Gynecol 2006;195:843-847.
19. Malone FD, Ball RH, Nyberg DA, et al. FASTER Trial Research Consortium. First-trimester septated cystic hygroma; prevalence, natural history, and pediatric outcome. Obstet Gynecol 2005;106:288-294.
20. Cleary-Goldman J, Berkowitz RL. First trimester screening for Down syndrome in multiple pregnancies. Semin Perinatol 2005;29:395-400.
21. Benn PA, Fang M, Egan JF, Horne D, Collins R. Incorporation of inhibin-A in second trimester screening for Down syndrome. Obstet Gynecol 2003; 101:451-454.
22. Neveux LM, Palomaki G, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 1996;16:29-34.
23. Palomaki GE, Bradley LA, McDowell GA; Down Syndrome Working Group; ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines: prenatal screening for Down syndrome. Genet Med 2005;7:344-354.
24. Smith-Bindman R, Chu P, Goldberg JD. Second trimester prenatal ultrasound for the detection of pregnancies at increased risk for Down syndrome. Prenat Diagn 2007;27:535-544.
25. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin Number 101: ultrasonography in pregnancy. Obstet Gynecol 2009;113:451-461.
26. Knight GJ, Palomaki GE, Neveux LM, et al. Integrated serum screening for Down syndrome in primary obstetric practice. Prenat Diagn 2005;25:1162-1167.
27. Platt LD, Greene N, Johnson A, et al; First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004;104:661-666.
28. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004;24:762-766.
29. Palomaki GE, Steinort K, Knight G, Haddow JE. Comparing three screening strategies for combining first-and second-trimester Down syndrome markers. Obstet Gynecol 2006;107:367-375.
30. Weisz B, Pandya P, Chitty L, Jones P, Huttly W, Rodeck C. Practical issues drawn from the implementation of the integrated test for Down syndrome screening into routine clinical practice. BJOG 2007;114:493-497.